Sutro Biopharma Inc (NASDAQ: STRO) kicked off on Monday, up 3.77% from the previous trading day, before settling in for the closing price of $2.65. Over the past 52 weeks, STRO has traded in a range of $2.45-$6.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 38.48% over the last five years. While this was happening, its average annual earnings per share was recorded -63.07%. With a float of $76.28 million, this company’s outstanding shares have now reached $82.40 million.
The firm has a total of 302 workers. Let’s measure their productivity. In terms of profitability, gross margin is 59.3%, operating margin of -80.79%, and the pretax margin is -67.19%.
Sutro Biopharma Inc (STRO) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sutro Biopharma Inc is 7.50%, while institutional ownership is 69.73%. The most recent insider transaction that took place on Jan 29 ’24, was worth 60,925. In this transaction CHIEF PORT. STRAT & ALNCE OFCR of this company sold 12,185 shares at a rate of $5.00, taking the stock ownership to the 12,803 shares.
Sutro Biopharma Inc (STRO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -63.07% per share during the next fiscal year.
Sutro Biopharma Inc (NASDAQ: STRO) Trading Performance Indicators
Take a look at Sutro Biopharma Inc’s (STRO) current performance indicators. Last quarter, stock had a quick ratio of 3.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -3.07 in one year’s time.
Technical Analysis of Sutro Biopharma Inc (STRO)
Analysing the last 5-days average volume posted by the [Sutro Biopharma Inc, STRO], we can find that recorded value of 0.75 million was lower than the volume posted last year of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 45.06%. Additionally, its Average True Range was 0.26.
During the past 100 days, Sutro Biopharma Inc’s (STRO) raw stochastic average was set at 11.03%, which indicates a significant decrease from 15.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.78% in the past 14 days, which was higher than the 84.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.44, while its 200-day Moving Average is $3.90. Now, the first resistance to watch is $2.82. This is followed by the second major resistance level at $2.88. The third major resistance level sits at $2.95. If the price goes on to break the first support level at $2.69, it is likely to go to the next support level at $2.62. Should the price break the second support level, the third support level stands at $2.56.
Sutro Biopharma Inc (NASDAQ: STRO) Key Stats
The company with the Market Capitalisation of 223.39 million has total of 82,459K Shares Outstanding. Its annual sales at the moment are 153,730 K in contrast with the sum of -106,790 K annual income. Company’s last quarter sales were recorded 8,520 K and last quarter income was -48,790 K.
